Sex differences in melanoma survival—a GEM study
JNCI Cancer Spectrum · 03.01.2025 · 9 (1)
DOI: 10.1093/jncics/pkaf005 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 12.01.2025. Verfasst von Tharani Murali und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, University of New Mexico, Albuquerque, NM 87131, United States. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Memorial Sloan Kettering Cancer Center, The UNC Lineberger Comprehensive Cancer Center.
Abstract (Originalsprache)
Sex differences in melanoma are prominent, with female having a significant survival advantage. However, it is unclear why we see this survival advantage. Here, we investigate the relationship between sex, clinicopathologic variables, and melanoma specific survival in 1753 single primary melanomas from patients in the GEM (Genes, Environment, and Melanoma) study. Using Cox proportional hazard models and formal mediation analysis, the effect of sex on survival is explained largely by differences in the clinicopathologic features of tumors at diagnosis. Specifically, we find evidence that 86.5% of the effect of sex on melanoma survival is mediated by differences in age at diagnosis, Breslow thickness, ulceration, mitoses, and site (hazard ratio [HR] = 1.85, P < .001). This analysis indicates that the female survival advantage in melanoma is not primarily due to a direct effect of sex (HR = 1.19, P = .42) but is largely a result of an indirect effect of sex mediated by clinicopathologic features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine, School of Medicine, University of New Mexico, Albuquerque, NM 87131, United States.
- College of Population Health, University of New Mexico, Albuquerque, NM 87131, United States.
- University of New Mexico Comprehensive Cancer Center, Division of Epidemiology, Biostatistics and Preventive Medicine, Albuquerque, NM 87131, United States.
- Department of Pathology, New York, NY 10065, United States.
- The Daffodil Center and the Melanoma Institute of Australia, School of Public Health, University of Sydney, Sydney, NSW 2050, Australia.
- Division of General Internal Medicine and Primary Care, Medicine, University of California at Irvine, Irvine, CA 92697, United States.
ORCID-Profile: Matthew Schwartz, Anne E Cust, Hoda Anton-Culver, Richard P Gallagher, Stefano Rosso, Lidia Sacchetto, Colin B Begg, Irene Orlow, Nancy E Thomas, Marianne Berwick
Förderung
- NCI NIH HHS
- Memorial Sloan Kettering Cancer Center
- The UNC Lineberger Comprehensive Cancer Center
- NIH HHS
- NHMR Investigator Fellowship
- University of New Mexico Comprehensive Cancer Center
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Murali, T., Schwartz, M., Reynolds, A. Z., Luo, L., Ridgeway, G., Busam, K. J., Cust, A. E., Anton-Culver, H., Gallagher, R. P., Zanetti, R., Rosso, S., Sacchetto, L., Begg, C. B., Orlow, I., Thomas, N. E., Berwick, M., & GEM Study Team (2025). Sex differences in melanoma survival—a GEM study. JNCI Cancer Spectrum, 9(1). https://doi.org/10.1093/jncics/pkaf005
Vancouver
Murali T, Schwartz M, Reynolds AZ, Luo L, Ridgeway G, Busam KJ, et al. Sex differences in melanoma survival—a GEM study. JNCI Cancer Spectrum. 2025;9(1). doi:10.1093/jncics/pkaf005
BibTeX
@article{Murali2025,
author = {Murali, Tharani and Schwartz, Matthew and Reynolds, Adam Z and Luo, Li and Ridgeway, Grace and Busam, Klaus J and Cust, Anne E and Anton-Culver, Hoda and Gallagher, Richard P and Zanetti, Roberto and Rosso, Stefano and Sacchetto, Lidia and Begg, Colin B and Orlow, Irene and Thomas, Nancy E and Berwick, Marianne and GEM Study Team, GEM Study Team},
title = {Sex differences in melanoma survival—a GEM study},
journal = {JNCI Cancer Spectrum},
year = {2025},
volume = {9},
number = {1},
doi = {10.1093/jncics/pkaf005}
}
EUVIMED